People with cystic fibrosis are prone to infections because of the thick, sticky mucus that clogs their airways. We are funding research to help fight these infections.
Site Search
People with cystic fibrosis have thick, sticky mucus that blocks passages in their lungs, making it difficult for them to breathe and predisposing them to infections. New drugs are under development that will help break up and hydrate mucus in the lungs to make it easier to clear.
Chronic inflammation in people with cystic fibrosis causes damage to lung tissue that can eventually lead to respiratory failure. Researchers are trying to discover ways to dampen the exaggerated immune response that causes chronic inflammation without affecting the body's natural defenses against infection.
People with cystic fibrosis can experience complications in the pancreas, liver, and intestines that can lead to malnutrition, constipation, liver disease, and other digestive issues — including abdominal pain and poor appetite. Learn about research underway to address digestive system issues in CF.
Cystic fibrosis-related diabetes (CFRD) is a unique type of diabetes that is common in people with CF. Learn about research underway to improve CFRD diagnosis and treatment.
Since the launch of the Infection Research Initiative in 2018, the Cystic Fibrosis Foundation has funded more than $100 million in research to improve the detection, diagnosis, treatment, and outcomes of CF-related infections.
The Cystic Fibrosis Foundation can help you engage people with cystic fibrosis so that you can incorporate their voices into the decision-making process throughout the development lifecycle of your
The Cystic Fibrosis Foundation is the world's leader in the fight against CF, and our scientific portfolio reflects our drive to provide effective treatments and — one day — a cure to every individual with this disease.
The patient-centered outcomes research (PCOR) training manual provides discrete steps, tools, and resources that CF Center research teams can take to integrate and maintain patient/caregiver-partners in CF research.